Janice Walsh

Absolutely not.

But is it hypothesis generating?

Yes.

And it needs to be tested in bigger populations.

But I think, you know, this is a development, as I said, that we are seeing in a range of different cancers and really is an indication as to why we're moving forward so fast.

So a lot of the research done over recent decades is coming to fruition now, because I know you said that things have changed in your area of breast cancer.

But when it comes to ovarian cancer, I think you said earlier that

the same drugs are in use that were used 20 years ago to treat that cancer.

Exactly right.

So, so today, if your cancer grows on what's called a platinum drug and you become platinum refractory, the drugs that we are using standard care up into this, um, Mervituximab was, um, showed its data were 20 years old.

And honestly, that is despite a huge effort in terms of trying to improve patients with this disease.

I think what would be important as well is they're also looking at this drug now at an earlier stage.

Um,

And while we think that patients need to express high levels of this folate receptor alpha, which is the target for this drug, we may even get benefit when we have lower levels of that expression and in front line.

So generally, when we see benefits of these drugs at later stages, what we want to do is bring it forward to see what these patients do better if we gave it earlier.

OK, so...

Were patients treated with this drug as a first line defence or do you have to still go through all of the other options and then use this?

So good question.

So the trial that was published there recently that came to the fore on the basis of the NHS approval.

was patients who had their cancer had grown on first-line treatment.